What's in Indivior's pipeline?

Indivior has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Indivior's portfolio?

Top competitors by shared drug class: Alkermes, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/indivior.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Indivior — Portfolio Competitive Intelligence Brief

Indivior (INDV.L) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

INDV.L (LSE) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Subutex	Buprenorphine Hydrochloride	marketed	partial opioid agonist	mu-opioid receptor, kappa-opioid receptor	Pain	1981-01-01

Therapeutic area mix

Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2027-07-23 — Subutex · 8147866 · Formulation · US
2027-07-23 — Subutex · 9655843 · Formulation · US
2032-12-21 — Subutex · 9901539 · Method of Use · US

Competitive overlap (companies sharing drug classes)

Alkermes, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Indivior:

Cite this brief

Drug Landscape (2026). Indivior — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/indivior. Accessed 2026-05-15.